Literature DB >> 11502541

Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae.

D J Bast1, J C de Azavedo, T Y Tam, L Kilburn, C Duncan, L A Mandell, R J Davidson, D E Low.   

Abstract

Analysis of 71 ciprofloxacin-resistant (MIC > or = 4 microg/ml) Streptococcus pneumoniae clinical isolates revealed only 1 for which the quinolone resistance-determining regions of the parC, parE, and gyrB genes were genetically related to those of viridans group streptococci. Our findings support the occurrence of interspecies recombination of type II topoisomerase genes; however, its contribution to the emergence of quinolone resistance among pneumococci appears to have been minimal.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11502541      PMCID： PMC90704          DOI： 10.1128/AAC.45.9.2631-2634.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  27 in total

1.  In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.

Authors:  K Nagai; T A Davies; G A Pankuch; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis.

Authors:  C Janoir; I Podglajen; M D Kitzis; C Poyart; L Gutmann
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

3.  Origin and molecular epidemiology of penicillin-binding-protein-mediated resistance to beta-lactam antibiotics.

Authors:  C G Dowson; T J Coffey; B G Spratt
Journal:  Trends Microbiol       Date:  1994-10       Impact factor: 17.079

4.  Deoxyribonucleic acid gyrase-deoxyribonucleic acid complex containing 140 base pairs of deoxyribonucleic acid and an alpha 2 beta 2 protein core.

Authors:  L Klevan; J C Wang
Journal:  Biochemistry       Date:  1980-11-11       Impact factor: 3.162

5.  Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.

Authors:  E Pestova; J J Millichap; G A Noskin; L R Peterson
Journal:  J Antimicrob Chemother       Date:  2000-05       Impact factor: 5.790

6.  Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.

Authors:  J Tankovic; B Perichon; J Duval; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

7.  Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.

Authors:  D J Bast; D E Low; C L Duncan; L Kilburn; L A Mandell; R J Davidson; J C de Azavedo
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

8.  Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.

Authors:  N P Brenwald; M J Gill; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

9.  Genetic and transcriptional organization of the region encoding the beta subunit of Bacillus subtilis RNA polymerase.

Authors:  K J Boor; M L Duncan; C W Price
Journal:  J Biol Chem       Date:  1995-09-01       Impact factor: 5.157

10.  Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.

Authors:  J H Jorgensen; L M Weigel; M J Ferraro; J M Swenson; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191
View more
  13 in total

Review 1.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

2.  Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae.

Authors:  Luz Balsalobre; María José Ferrándiz; Josefina Liñares; Fe Tubau; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

3.  Interspecies recombination in type II topoisomerase genes is not a major cause of fluoroquinolone resistance in invasive Streptococcus pneumoniae isolates in the United States.

Authors:  Mathias W R Pletz; Lesley McGee; Bernard Beall; Cynthia G Whitney; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 4.  Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Authors:  A Dalhoff
Journal:  Infection       Date:  2012-03-30       Impact factor: 3.553

5.  Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.

Authors:  Heather J Adam; Kristen N Schurek; Kimberly A Nichol; Chris J Hoban; Trish J Baudry; Nancy M Laing; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

6.  Fluoroquinolone-resistant Streptococcus pneumoniae strains occur frequently in elderly patients in Japan.

Authors:  Shin-Ichi Yokota; Kiyoshi Sato; Osamu Kuwahara; Satoshi Habadera; Naoyuki Tsukamoto; Hironori Ohuchi; Hirotsugu Akizawa; Tetsuo Himi; Nobuhiro Fujii
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

7.  Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.

Authors:  Luz Balsalobre; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

8.  Genetic characterization of optochin-susceptible viridans group streptococci.

Authors:  Antonio J Martín-Galiano; Luz Balsalobre; Asunción Fenoll; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 9.  Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.

Authors:  Lindsay Kim; Lesley McGee; Sara Tomczyk; Bernard Beall
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

10.  Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain.

Authors:  Adela G de la Campa; Carmen Ardanuy; Luz Balsalobre; Emilio Pérez-Trallero; Jose M Marimón; Asunción Fenoll; Josefina Liñares
Journal:  Emerg Infect Dis       Date:  2009-06       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.